[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon with the NYSE Health Care Index and the Health Care Se",
    "url": "https://finnhub.io/api/news?id=d401c27aa240608b6a4853b1219c1fcf47de6d6a689227680af463f953ecae54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756497598,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 136576287,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon with the NYSE Health Care Index and the Health Care Se",
      "url": "https://finnhub.io/api/news?id=d401c27aa240608b6a4853b1219c1fcf47de6d6a689227680af463f953ecae54"
    }
  },
  {
    "ts": null,
    "headline": "ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?",
    "summary": "As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?",
    "url": "https://finnhub.io/api/news?id=f99e9bc84f5ed48fb8e12e082c1568899c2eb8830bae89f09a0f8b231af02b0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756475280,
      "headline": "ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?",
      "id": 136569225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?",
      "url": "https://finnhub.io/api/news?id=f99e9bc84f5ed48fb8e12e082c1568899c2eb8830bae89f09a0f8b231af02b0e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis",
    "summary": "Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company's Navitor™ transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. Abbott previously received CE Mark in 2021 for Navitor to treat people with symptomatic, severe aortic stenosis who are at high or extreme surgical risk. With this new approval, Navitor is available in Euro",
    "url": "https://finnhub.io/api/news?id=9e6e2c87dd8072e1917de78a7acb0ea5f09638bcd895e32c4e4987b7572cfabc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756468800,
      "headline": "Abbott's Navitor™ TAVI System Receives CE Mark for Expanded Indication to Treat More People With Aortic Stenosis",
      "id": 136569226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for an expanded indication for the company's Navitor™ transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. Abbott previously received CE Mark in 2021 for Navitor to treat people with symptomatic, severe aortic stenosis who are at high or extreme surgical risk. With this new approval, Navitor is available in Euro",
      "url": "https://finnhub.io/api/news?id=9e6e2c87dd8072e1917de78a7acb0ea5f09638bcd895e32c4e4987b7572cfabc"
    }
  },
  {
    "ts": null,
    "headline": "The Bottom Fishing Club - Avanos Medical: Bargain Defensive Choice",
    "summary": "Discover why Avanos Medical, Inc. offers a compelling turnaround investment. Click for more on AVNS stock and why I think it is a bargain.",
    "url": "https://finnhub.io/api/news?id=7ac750ce261a2616c49d2d4fb8e39249356f45e5af8115fcbb43d8e949b717f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756461659,
      "headline": "The Bottom Fishing Club - Avanos Medical: Bargain Defensive Choice",
      "id": 136568611,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2219875002/image_2219875002.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Discover why Avanos Medical, Inc. offers a compelling turnaround investment. Click for more on AVNS stock and why I think it is a bargain.",
      "url": "https://finnhub.io/api/news?id=7ac750ce261a2616c49d2d4fb8e39249356f45e5af8115fcbb43d8e949b717f8"
    }
  },
  {
    "ts": null,
    "headline": "2 Reasons to Watch ABBV and 1 to Stay Cautious",
    "summary": "AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.",
    "url": "https://finnhub.io/api/news?id=7aab52c2104925d71b48e74163be45641a0a0f58c040db83f7c4f0addc3da604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756440194,
      "headline": "2 Reasons to Watch ABBV and 1 to Stay Cautious",
      "id": 136569140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "AbbVie currently trades at $207.60 per share and has shown little upside over the past six months, posting a small loss of 0.7%. The stock also fell short of the S&P 500’s 9.2% gain during that period.",
      "url": "https://finnhub.io/api/news?id=7aab52c2104925d71b48e74163be45641a0a0f58c040db83f7c4f0addc3da604"
    }
  }
]